14 articles - From Friday Dec 26 2025 to Friday Jan 02 2026
Guidelines and related publications, position statements, white papers, technical reviews, consensus statements, etc…
meta-analyses and systematic reviews
RCT, clinical trials, retrospective studies, etc…
| Aliment Pharmacol Ther |
|---|
| Advanced Fibrosis and Cardiometabolic Risk Burden Increase Major Cardiovascular Events in Chronic Hepatitis C Patients With Steatotic Liver Disease After Viral Eradication.
CMRFs burden, advanced fibrosis, and CKD predicted MACEs in CHC patients with MASLD after achieving SVR. CMRFs monitoring and management should be prioritised in high-risk patients. |
| Barriers to Medical Care Are Frequently Reported by Patients With Cirrhosis.
Patients with cirrhosis report frequent barriers to medical care including limited access to clinic appointments, although barriers vary by healthcare system. Barriers to care serve as intervention targets to improve outcomes for patients with cirrhosis. |
| Clin Gastroenterol Hepatol |
| Psychometric Development and Internal Validation of a Short Version of the Crohn's Anal Fistula Quality of Life Scale.
CAFQOL is a reliable and responsive tool that captures meaningful changes over time. The short CAFQOL is a feasible tool for repeated disease monitoring. |
| Gut |
| <i>Parasutterella excrementihominis</i> exacerbates experimental colitis and colitis-associated colorectal cancer via pathogenic NETosis activation.
This bacterium significantly accelerates disease progression by producing specific metabolites (Suc and 6-HHA) that induce pathogenic NETosis. Targeting this bacterium or its metabolic axis offers novel therapeutic strategies for inflammation-driven colorectal carcinogenesis. |
| TL1A-activated T cells remodel the rectal mucosa in patients with Crohn's disease with perianal fistulising disease.
Our findings revealed unique cellular alterations in the rectum of patients with CD+PFD, highlighting the previously unrecognised involvement of TL1A in mediating this signature and supporting the need for exploring the role of TL1A inhibition as a therapeutic approach for PFD. |
| Targeting cancer stem cells enhances multikinase inhibitor therapy in metabolic dysfunction-associated steatotic liver disease-related hepatocellular carcinoma.
This study established CD133 + CSCs as critical mediators through the CD133-MYH9/β-catenin axis in MASLD-HCC. Targeting CD133 enhances multikinase inhibitor efficacy, offering a promising therapeutic strategy for MASLD-HCC. |
| Hepatology |
| Head-to-head comparison between vibration-controlled transient elastography and histology in predicting liver-related events due to metabolic dysfunction-associated steatotic liver disease.
In this large MASLD cohort, LSM by VCTE showed comparable prognostic accuracy to histology. As a non-invasive tool, LSM may serve as an alternative surrogate endpoint in clinical trials. |
Plenty of the editorials are available as full text through the publisher website using the provided link
| Aliment Pharmacol Ther |
|---|
| Editorial: Combination Therapies for MASH: A Step Forward or More Complexity? |
misc publications eg case reports, tools of the trade, images of the month, etc…
| Clin Gastroenterol Hepatol |
|---|
| Assessing predictive performance of FIB-4 in settings with lower prevalence of liver fibrosis. |
| Baked and Limited Regular Milk is Tolerated in Adults with Milk-Triggered Eosinophilic Esophagitis: A Prospective Pilot Study. |
| Open-label, phase 2a pilot study evaluating the efficacy and tolerability of topical mesalamine treatment in adult patients with active eosinophilic esophagitis. |
Letters to the editors and authors’ replies
| Aliment Pharmacol Ther |
|---|
| Editorial: Combination Therapies for MASH: A Step Forward or More Complexity? Authors' Reply. |
| Gastroenterology |
| Celiac disease diagnosis on a gluten-free diet: unresolved issues. |
| J Hepatol |
| Development and validation of a prognostic model for MASLD identifying hypertension as a pivotal factor: A population-based study. |